NCT00655655 2024-08-21
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Phase 1 Completed
Clinical Trials
26 trialsNCT00358163 2022-04-29
Trial of PTK787/ZK 222584 Plus Paclitaxel
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT00615160 2021-10-06
PTK/ZK in Disseminated Malignant Melanoma
University Hospital Schleswig-Holstein
Phase 1/2 Terminated
NCT00390000 2019-04-08
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Phase 1 Completed
NCT00348790 2018-10-26
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
Northwestern University
Phase 2 Completed
NCT00268918 2018-07-27
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00072475 2016-08-01
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00053885 2016-07-01
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00303732 2016-03-03
PTK/RAD
Duke University
Phase 1 Completed
NCT00216047 2015-12-09
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT00387933 2015-10-14
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Duke University
Phase 1 Completed
NCT00134355 2015-01-19
Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00511043 2014-12-09
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
Duke University
Phase 2 Terminated
NCT00240162 2014-09-17
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma
Washington University School of Medicine
Phase 2 Terminated
NCT00185588 2014-09-15
Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
Stanford University
Phase 1/2 Completed
NCT00731861 2014-09-11
Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors
Indiana University
Phase 1 Completed
NCT00385853 2013-10-21
PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
Massachusetts General Hospital
Phase 1 Completed
NCT00263198 2013-05-07
PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT00293371 2012-10-11
Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer
University of California, San Francisco
Phase 1/2 Terminated
NCT00226005 2012-05-09
PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer Research Team
Phase 2 Completed
NCT00281125 2012-03-19
Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer
Nevada Cancer Institute
Phase 1/2 Terminated
NCT00088231 2012-01-20
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00590343 2011-06-29
PTK787
Louisiana State University Health Sciences Center in New Orleans
Phase 2 Completed
NCT00117299 2010-05-27
PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib
University of Helsinki
Phase 2 Completed
NCT00611793 2009-01-23
PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00165347 2007-12-21
Protein Tyrosine Kinases (PTK) in Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed